Self-inactivating helper virus for the production of high-capacity adenoviral vectors

被引:0
|
作者
M Gonzalez-Aparicio
I Mauleon
P Alzuguren
M Bunuales
G Gonzalez-Aseguinolaza
C San Martín
J Prieto
R Hernandez-Alcoceba
机构
[1] CIMA,Division of Hepatology and Gene Therapy
[2] University of Navarra,Department of Macromolecular Structure
[3] Foundation for Applied Medical Research,undefined
[4] Centro Nacional de Biotecnología (CNB-CSIC),undefined
[5] CIBERehd,undefined
[6] University Clinic of Navarra,undefined
来源
Gene Therapy | 2011年 / 18卷
关键词
helper adenovirus; cre recombinase; high-capacity adenovirus; tet-on system;
D O I
暂无
中图分类号
学科分类号
摘要
Standard methods for producing high-capacity adenoviral vectors (HC-Ads) are based on co-infection with a helper adenovirus (HV). To avoid HV encapsidation, its packaging signal (Ψ) is flanked by recognition sequences for recombinases expressed in the producing cells. However, accumulation of HV and low yield of HC-Ad are frequently observed, due in part to insufficient recombinase expression. We describe here a novel HV (AdTetCre) in which Ψ is flanked by loxP sites that can be excised by a chimeric MerCreMer recombinase encoded in the same viral genome. Efficient modulation of cleavage was obtained by simultaneous control of MerCreMer expression using a tet-on inducible system, and translocation to the nucleus by 4-hydroxytamoxifen (TAM). Encapsidation of AdTetCre was strongly inhibited by TAM plus doxycicline. Using AdTetCre and 293Cre4 cells for the production of HC-Ads, we found that cellular and virus-encoded recombinases cooperate to minimize HV contamination. The method was highly reproducible and allowed the routine production of different HC-Ads in a medium-scale laboratory setting in adherent cells, with titers >1010 infectious units and <0.1% HV contamination. The residual HVs lacked Ψ and were highly attenuated. We conclude that self-inactivating HVs based on virally encoded recombinases are promising tools for the production of HC-Ads.
引用
收藏
页码:1025 / 1033
页数:8
相关论文
共 50 条
  • [21] A clinical-grade constitutive packaging cell line for the production of self-inactivating lentiviral vectors
    Knight, Sean
    Sanber, Khaled
    Stephen, Sam
    Bailey, Ranbir
    Escors, David
    Santilli, Giorgia
    Thrasher, Adrian
    Collins, Mary
    Takeuchi, Yasu
    HUMAN GENE THERAPY, 2013, 24 (05) : A23 - A23
  • [22] A clinical-grade constitutive packaging cell line for the production of self-inactivating lentiviral vectors
    Knight, Sean
    Sanber, Khaled
    Stephen, Sam
    Ferraresso, Marta
    Baley, Ranbir
    Escors, David
    Santilli, Giorgia
    Thrasher, Adrian
    Collins, Mary
    Takeuchi, Yasu
    HUMAN GENE THERAPY, 2014, 25 (11) : A101 - A102
  • [23] Rapid Adenoviral Capsid Engineering (RACE) Platform for High-Throughput Modification of High-Capacity Adenoviral Vectors
    Hausl, Martin A.
    Ruzsics, Zsolt
    Ehrhardt, Anja
    MOLECULAR THERAPY, 2009, 17 : S282 - S283
  • [24] Insertional Transformation of Hematopoietic Cells by Self-inactivating Lentiviral and Gammaretroviral Vectors
    Modlich, Ute
    Navarro, Susana
    Zychlinski, Daniela
    Maetzig, Tobias
    Knoess, Sabine
    Brugman, Martijn H.
    Schambach, Axel
    Charrier, Sabine
    Galy, Anne
    Thrasher, Adrian J.
    Bueren, Juan
    Baum, Christopher
    MOLECULAR THERAPY, 2009, 17 (11) : 1919 - 1928
  • [25] Kinetics and characteristics of replication-competent revertants derived from self-inactivating foamy virus vectors
    Bastone, P
    Löchelt, M
    GENE THERAPY, 2004, 11 (05) : 465 - 473
  • [26] Evaluation of Residual Promoter Activity in γ-Retroviral Self-inactivating (SIN) Vectors
    Xu, Wenqin
    Russ, Jill L.
    Eiden, Maribeth V.
    MOLECULAR THERAPY, 2012, 20 (01) : 84 - 90
  • [27] Generation of a stable cell line producing high-titer self-inactivating lentiviral vectors
    Xu, KL
    Ma, H
    McCown, TJ
    Verma, IM
    Kafri, T
    MOLECULAR THERAPY, 2001, 3 (01) : 97 - 104
  • [28] Cloning and Large-Scale Production of High-Capacity Adenoviral Vectors Based on the Human Adenovirus Type 5
    Ehrke-Schulz, Eric
    Zhang, Wenli
    Schiwon, Maren
    Bergmann, Thorsten
    Solanki, Manish
    Liu, Jing
    Boehme, Philip
    Leitner, Theo
    Ehrhardt, Anja
    JOVE-JOURNAL OF VISUALIZED EXPERIMENTS, 2016, (107):
  • [29] Molecular Determination of High-Capacity Helper Dependent Adenoviral Vector Genomes In Vitro and In Vivo
    Puntel, Mariana
    Curtin, James F.
    Zirger, Jeffrey M.
    Muhammad, A. K. M.
    Weidong, Xiong
    Liu, Chunyan
    Hu, Jinwei
    Kroeger, Kurt M.
    Czer, Peter
    Sciascia, Sandra
    Lowenstein, Pedro R.
    Castro, Maria G.
    MOLECULAR THERAPY, 2006, 13 : S328 - S328
  • [30] Kinetics and characteristics of replication-competent revertants derived from self-inactivating foamy virus vectors
    P Bastone
    M Löchelt
    Gene Therapy, 2004, 11 : 465 - 473